Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Information Technology

Harpoon Therapeutics

Harpoon Therapeutics' headquarters in South San Francisco, CA, United States

Luke Walker

Banmeet Anand

Grace Wang

Alpana Naresh

Rick Austin

Chen Fang

Julia Bushkov

Yu Ding

May Dayao

Susan Carpenter

Chatan Charan

Phoebe Chua

Ron Hunt

Jeffrey Ravetch

Charles Rudin

Jonathan Drachman

Andrew Robbins

Joseph S. Bailes

Ramy Ibrahim

Mark Chin

Description

People (9)

Kathleen B.